Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

Yu Zhou, Shasha Wang, Yunxia Tao, Haizhu Chen, Yan Qin, Xiaohui He, Shengyu Zhou, Peng Liu, Jianliang Yang, Sheng Yang, Lin Gui, Ning Lou, Zhishang Zhang, Jiarui Yao, Xiaohong Han, Yuankai ShiJournal of Translational Medicine 2021 · DOI

Abstract

CCL19 expression was associated with survival outcomes and might be a potential prognostic biomarker for follicular lymphoma (FL) treated with first-line chemoimmunotherapy.

Introduction

Follicular lymphoma (FL) is typically an indolent B-cell malignancy characterized by a relapsing-remitting clinical course. Despite the success of rituximab-based chemoimmunotherapy, approximately 20% of patients experience disease progression within 24 months of diagnosis (POD24), which is associated with poor long-term survival. Currently, clinical tools like the Follicular Lymphoma International Prognostic Index (FLIPI) are used for risk stratification, but they often fail to capture the biological heterogeneity of the disease. This study aims to identify novel "hub genes"—central nodes in gene co-expression networks—that can serve as reliable prognostic biomarkers to identify high-risk patients before treatment.

Methods and Data Sources

The researchers utilized a multi-stage approach combining computational biology with clinical validation:

  1. Gene Discovery: Weighted Gene Co-expression Network Analysis (WGCNA) was applied to the GSE65135 dataset (14 FL tissues and 10 normal controls) to identify clusters of co-expressed genes and hub genes.
  2. Validation Cohorts: Findings were validated using a larger microarray dataset (GSE119214, n=137) and an independent clinical cohort from the Cancer Hospital, Chinese Academy of Medical Sciences (CHCAMS, n=32).
  3. Protein Analysis: Serum CCL19 levels in the CHCAMS cohort were measured using Enzyme-Linked Immunosorbent Assay (ELISA).
  4. Immune Microenvironment: The CIBERSORT algorithm was used to estimate the infiltration of 22 types of immune cells, exploring the relationship between biomarker expression and the tumor microenvironment.
Identification and functional enrichment analysis of differentially expressed genes (DEGs) in follicular lymphoma.

Key Insights: The Role of CCL19

The analysis identified eight hub genes, with CCL19 (C-C Motif Chemokine Ligand 19) emerging as the most significant independent predictor of survival. CCL19 is a chemokine primarily involved in the trafficking of T cells and dendritic cells to secondary lymphoid organs.

The study revealed that high CCL19 expression is linked to a more robust anti-tumor immune environment. Specifically, high levels of CCL19 correlated with increased infiltration of M1 macrophages (pro-inflammatory/anti-tumor) and decreased proportions of naïve B cells. Conversely, low CCL19 expression may characterize an "immune-cold" tumor microenvironment, potentially allowing the cancer to evade detection and destruction by the immune system.

Clinical Results and Survival Outcomes

The prognostic value of CCL19 was consistent across genetic and protein levels:

  • Genetic Level: In the validation dataset, high CCL19 mRNA expression was associated with significantly better Overall Survival (OS). Multivariate analysis confirmed CCL19 as an independent prognostic factor with a Hazard Ratio (HR) of 0.47.
  • Serum Level: In the CHCAMS cohort, a serum CCL19 concentration cutoff of 0.94 ng/ml was established. Patients with serum levels above this threshold demonstrated significantly longer Progression-Free Survival (PFS, p=0.014) and Overall Survival (p=0.039).
  • Independence: CCL19 remained a significant predictor even when adjusted for other clinical variables, including the FLIPI score and rituximab maintenance therapy.

Discussion and Limitations

This study highlights CCL19 as a promising non-invasive biomarker for FL prognosis. The ability to measure this marker in patient serum suggests a potential "liquid biopsy" application that could complement existing tissue-based diagnostics.

However, several limitations remain. The clinical validation cohort was relatively small (n=32), and the follow-up period was insufficient for a definitive multivariate analysis of overall survival in this specific group. Furthermore, while the correlation between CCL19 and survival is strong, the underlying biological mechanisms remain to be fully elucidated. Future research should focus on larger multi-center trials to standardize the serum cutoff and experimental studies to determine if modulating CCL19 levels could enhance the efficacy of immunotherapies like CAR-T cell treatment.

Summary updated

Abstract

CCL19 expression was associated with survival outcomes and might be a potential prognostic biomarker for FL treated with first-line chemoimmunotherapy.
BibTeX
@article{zhou2021low,
  author = {Yu Zhou and Shasha Wang and Yunxia Tao and Haizhu Chen and Yan Qin and Xiaohui He and Shengyu Zhou and Peng Liu and Jianliang Yang and Sheng Yang and Lin Gui and Ning Lou and Zhishang Zhang and Jiarui Yao and Xiaohong Han and Yuankai Shi},
  title = {{Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy}},
  journal = {Journal of Translational Medicine},
  year = {2021},
  doi = {10.1186/s12967-021-03078-9},
}
Figure